سعر انجيوبرادين 7.5 مجم 30 قرص 2022

Ivabradine 7.5 mg film-coated tablets (If-channel inhibitor), pack of 30 tablets, produced by Future Pharmaceutical Industries for Tabuk Pharmaceutical Manufacturing Company.

• Symptomatic treatment of chronic stable angina pectoris in adults with coronary artery disease, normal sinus rhythm and heart rate >= 70 bpm, intolerant of/contraindicated to beta-blockers or in combination with beta-blockersPopulation: Adultselectronic medicines compendium (emc), UK
• Chronic heart failure NYHA II-IV with systolic dysfunction, sinus rhythm and heart rate >= 75 bpm, with standard therapyPopulation: Adultselectronic medicines compendium (emc), UK
• To reduce the risk of hospitalization for worsening heart failure in adults with stable symptomatic chronic heart failure, LVEF <= 35%, sinus rhythm with resting heart rate >= 70 bpm, on maximally tolerated beta-blockers or with a contraindicationPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common: luminous phenomena (phosphenes, 14.5%) and bradycardia (3.3%), dose dependent; headache and dizziness common.International label, same formulation · electronic medicines compendium (emc), UK
• In heart failure trials: bradycardia (10%), hypertension/increased blood pressure (8.9%), atrial fibrillation (8.3%), luminous phenomena (2.8%).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Resting heart rate below 70 bpm before treatment; cardiogenic shock; acute myocardial infarction; severe hypotension (< 90/50 mmHg).International label, same formulation · electronic medicines compendium (emc), UK
• Sick sinus syndrome, sino-atrial block, third-degree AV block, pacemaker dependence, unstable or acute heart failure, unstable angina.International label, same formulation · electronic medicines compendium (emc), UK
• Severe hepatic insufficiency.International label, same formulation · electronic medicines compendium (emc), UK

• Indicated only for symptomatic treatment of stable angina: no demonstrated benefit on cardiovascular outcomes. Reduce the dose if resting heart rate falls below 50 bpm or bradycardia symptoms occur; stop if they persist.International label, same formulation · electronic medicines compendium (emc), UK
• Increased risk of atrial fibrillation; monitor cardiac rhythm.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Bradycardia and conduction disturbances; risk increased with other negative chronotropes.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, erythromycin oral, HIV protease inhibitors, nefazodone)Contraindicated: markedly increase ivabradine exposure.electronic medicines compendium (emc), UK
• Verapamil, diltiazemContraindicated: moderate CYP3A4 inhibitors with additional heart-rate lowering.electronic medicines compendium (emc), UK
• Negative chronotropes (e.g., digoxin, amiodarone, beta-blockers)Additive heart-rate lowering; monitor heart rate.DailyMed (U.S. National Library of Medicine)

• Contraindicated in pregnancy: animal studies showed embryotoxic and teratogenic effects; women of child-bearing potential must use appropriate contraception.International label, same formulation · electronic medicines compendium (emc), UK
• Contraindicated during breast-feeding (excreted in animal milk).International label, same formulation · electronic medicines compendium (emc), UK

• Ivabradine: Selectively inhibits the If ("funny") current in the sinoatrial node, slowing diastolic depolarisation and lowering heart rate without affecting contractility.